Your browser doesn't support javascript.
loading
A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies.
Lameris, Roeland; Ruben, Jurjen M; Iglesias-Guimarais, Victoria; de Jong, Milon; Veth, Myrthe; van de Bovenkamp, Fleur S; de Weerdt, Iris; Kater, Arnon P; Zweegman, Sonja; Horbach, Sjeng; Riedl, Thilo; Winograd, Benjamin; Roovers, Rob C; Adang, Anton E P; de Gruijl, Tanja D; Parren, Paul W H I; van der Vliet, Hans J.
Affiliation
  • Lameris R; Amsterdam UMC location Vrije University Amsterdam, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Ruben JM; LAVA Therapeutics, Utrecht, the Netherlands.
  • Iglesias-Guimarais V; LAVA Therapeutics, Utrecht, the Netherlands.
  • de Jong M; Amsterdam UMC location Vrije University Amsterdam, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Veth M; Amsterdam UMC location Vrije University Amsterdam, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • van de Bovenkamp FS; LAVA Therapeutics, Utrecht, the Netherlands.
  • de Weerdt I; Amsterdam UMC location University of Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Kater AP; Amsterdam UMC location University of Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Zweegman S; Amsterdam UMC location Vrije University Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Horbach S; J&S Preclinical Solutions, Oss, the Netherlands.
  • Riedl T; LAVA Therapeutics, Utrecht, the Netherlands.
  • Winograd B; LAVA Therapeutics, Utrecht, the Netherlands; LAVA Therapeutics, Philadelphia, PA, USA.
  • Roovers RC; LAVA Therapeutics, Utrecht, the Netherlands.
  • Adang AEP; LAVA Therapeutics, Utrecht, the Netherlands.
  • de Gruijl TD; Amsterdam UMC location Vrije University Amsterdam, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Parren PWHI; LAVA Therapeutics, Utrecht, the Netherlands; Leiden University Medical Center, Department of Immunology, Leiden, the Netherlands.
  • van der Vliet HJ; Amsterdam UMC location Vrije University Amsterdam, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, the Netherlands; LAVA Therapeutics, Utrecht, the Netherlands. Electronic address: h.vandervliet@lavatherapeutics.com.
Cell Rep Med ; 4(3): 100961, 2023 03 21.
Article in En | MEDLINE | ID: mdl-36868236
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / Leukemia, Myeloid, Acute / Hematologic Neoplasms Limits: Animals Language: En Journal: Cell Rep Med Year: 2023 Document type: Article Affiliation country: Netherlands Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / Leukemia, Myeloid, Acute / Hematologic Neoplasms Limits: Animals Language: En Journal: Cell Rep Med Year: 2023 Document type: Article Affiliation country: Netherlands Country of publication: United States